Alliance Pharma PLC PDMR shareholding (8887W)

TIDMAPH

RNS Number : 8887W

Alliance Pharma PLC

14 February 2017

 
 For immediate release   14 February 2017 
 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

PDMR shareholding

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that Peter Butterfield, a director of the Company and its Deputy CEO has today exercised an option granted under an employee share scheme over 90,222 ordinary shares of 1p each in the Company at 33.25p per share, and immediately sold 61,846 of these shares on the London Stock Exchange at a price of 48.75p per share to fund the subscription price and associated dealing costs.

Following these linked transactions, Mr Butterfield has a beneficial interest in 28,376 shares in the Company and holds options over a further 4,349,803 shares granted under the Company's employee share schemes.

For further information:

 
 Alliance Pharma plc                             + 44 (0) 1249 466966 
 John Dawson, Chief Executive 
  Andrew Franklin, Chief Financial 
  Officer 
 Rob Bellhouse, Company Secretary 
 www.alliancepharma.co.uk 
                                                     + 44 (0) 20 7466 
 Buchanan                                                        5000 
 Mark Court / Sophie Cowles 
  / Jane Glover 
 
                                                     + 44 (0) 20 7260 
 Numis Securities Limited                                        1000 
 Nominated Adviser: Michael 
  Meade / Freddie Barnfield 
 Corporate Broking: James 
  Black / Toby Adcock 
 

Notes to editors:

About Alliance Pharma

Alliance, founded in 1998, is an international speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors. Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

ANNEX

Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
 1    Details of the person discharging managerial 
       responsibilities / person closely associated 
---  --------------------------------------------------------------- 
 a)   Name                       Peter Butterfield 
---  -------------------------  ------------------------------------ 
 2    Reason for the notification 
---  --------------------------------------------------------------- 
 a)   Position/status            Deputy Chief Executive Officer 
---  -------------------------  ------------------------------------ 
 b)   Initial notification       Initial 
       /Amendment 
---  -------------------------  ------------------------------------ 
 3    Details of the issuer, emission allowance 
       market participant, auction platform, auctioneer 
       or auction monitor 
---  --------------------------------------------------------------- 
 a)   Name                       Alliance Pharma plc 
---  -------------------------  ------------------------------------ 
 b)   LEI                        n/a 
---  -------------------------  ------------------------------------ 
 4    Details of the transaction(s): section 
       to be repeated for (i) each type of instrument; 
       (ii) each type of transaction; (iii) each 
       date; and (iv) each place where transactions 
       have been conducted 
---  --------------------------------------------------------------- 
 a)   Description of             1p ordinary shares 
       the financial 
       instrument, type           ISIN: GB0031030819 
       of instrument 
 
       Identification 
       code 
---  -------------------------  ------------------------------------ 
 b)   Nature of the                   1. Exercise of options 
       transaction                     2. Sale 
---  -------------------------  ------------------------------------ 
 c)   Price(s) and volume(s)      Price(s)          Volume(s) 
                                  ----------------  ---------------- 
                                        1) 33.25p         1) 90,222 
                                         2) 48.75p         2) 61,846 
                                  ----------------  ---------------- 
---  -------------------------  ------------------------------------ 
 d)   Aggregated information     Exercise of 90,222 options 
                                  at an exercise price of 33.25p 
                                  per share 
       - Aggregated volume 
                                  Sale of 61,846 shares at 
                                  a price of 48.75p per share 
       - Price 
---  -------------------------  ------------------------------------ 
 e)   Date of the transaction    14 February 2017 
---  -------------------------  ------------------------------------ 
 f)   Place of the transaction   London Stock Exchange, AIM 
---  -------------------------  ------------------------------------ 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHBRGDDRDBBGRS

(END) Dow Jones Newswires

February 14, 2017 12:31 ET (17:31 GMT)